Cardiac Pathologies in Standard Thoracic CT Imaging
CaPaCT
Evaluation of Cardiac Pathologies in Standard Thoracic CT Imaging [CaPaCT]
1 other identifier
observational
221
1 country
1
Brief Summary
Modern high-end CT scanners with faster scan acquisition times now allow for routine assessment of cardiac pathologies, which could result in numerous incidental cardiac findings on standard thoracic CT angiography (CTA) scans. The CaPaCT-study aims to assesses the presence, management and possible clinical impact of incidental cardiac pathologies which are becoming visible on standard thoracic CT scans performed on new high-end scanners.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2016
CompletedFirst Submitted
Initial submission to the registry
September 13, 2016
CompletedFirst Posted
Study publicly available on registry
September 16, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 5, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
March 5, 2018
CompletedMay 2, 2018
September 1, 2017
1.7 years
September 13, 2016
April 30, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evaluate visibility and management of coronary artery disease (CAD)
Evaluating visibility and management of CAD on standard thoracic CT with help of the CAD-RAD system.
One year
Secondary Outcomes (2)
Objective image quality
One year
Subjective image quality
One year
Eligibility Criteria
All consecutive patients referred for thoracic CT-scanning.
You may qualify if:
- \- Standard non-ECG triggered thoracic CT scanning.
You may not qualify if:
- Iodine allergy
- Renal insufficiency (GFR \< 30mL/min)
- Pregnancy
- Age \< 18 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Maastricht University Medical Centerlead
- Bayercollaborator
Study Sites (1)
Maastricht University Medical Center
Maastricht, Limburg, 6202AZ, Netherlands
Related Publications (3)
Khakoo AY, Yeh ET. Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol. 2008 Nov;5(11):655-67. doi: 10.1038/ncponc1225. Epub 2008 Sep 16.
PMID: 18797437BACKGROUNDKannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979 May 11;241(19):2035-8. doi: 10.1001/jama.241.19.2035.
PMID: 430798BACKGROUNDAktas MK, Ozduran V, Pothier CE, Lang R, Lauer MS. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. JAMA. 2004 Sep 22;292(12):1462-8. doi: 10.1001/jama.292.12.1462.
PMID: 15383517BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 13, 2016
First Posted
September 16, 2016
Study Start
July 1, 2016
Primary Completion
March 5, 2018
Study Completion
March 5, 2018
Last Updated
May 2, 2018
Record last verified: 2017-09